
Conference Coverage
about 5 hours ago
Safe Contraceptive Options for Perimenopausal Women in 2025about 8 hours ago
Personalizing Menopause Treatment for Uncommon SymptomsLatest Content

Radiotherapy Plus Chemo Benefits Certain Patients With DLBCL

FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma

Eliminating Cost Sharing Boosted Follow-Up Colonoscopy Rates

How HRV Biofeedback Eases Mental Stress in Coronary Artery Disease

Safe Contraceptive Options for Perimenopausal Women in 2025

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Explore the critical implications of proposed Medicaid cuts on health care access, costs, and community well-being in the US.

Different cultural, linguistic, and systemic barriers could impact how Indigenous and Hispanic women access menopause care, said Lisa Taylor-Swanson, PhD.

Can women feel relief from tinnitus and burning mouth syndrome during perimenopause and menopause?

Medicare Advantage grocery supplemental benefit use is associated with increased outpatient care, suggesting that policy changes allowing for nonmedical supplemental benefits could improve beneficiaries’ health, especially for dual-eligible beneficiaries.

A novel combination therapy enhances the effectiveness of proteasome inhibitors against acute myeloid leukemia (AML), improving survival rates in preclinical models.

A study reveals promising results for combining enfortumab vedotin and pembrolizumab in treating recurrent head and neck cancer, showing a 39% response rate.

Patients with fatty liver disease are significantly more likely to develop kidney stones, a national study found.

Dana-Farber researchers have uncovered mutation pathways driving aggressive disease transformation.

Venetoclax plus bortezomib and dexamethasone improved PFS in relapsed/refractory multiple myeloma, especially in patients with BCL2high disease.

A targeted therapy combination achieved complete remission in a CAR-positive PTCL patient post-CAR T-cell therapy for multiple myeloma.